Drug Trial Radar · NCT05588908
A Phase Ib/II Study of Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection in Chinese Participants With Acute Gout
Last checked: Nov 19, 2026Latest source record: Oct 20, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
120
Planned (sponsor's estimate)
Start
Jun 29, 2022
Primary completion
Sep 2023
Study completion Nov 2023
Sponsor
- Lead sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Oct 20, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine the target dose of phase II and to evaluate the safety, tolerability, pharmacokinetics and efficacy of recombinant anti-IL-1β humanized monoclonal antibody injection at different doses in Chinese participants with acute gout.
Conditions
- Acute Gout
Interventions
Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 100 mg (phase Ib)Drug
100 mg subcutaneous (s.c) once
Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 200 mg (phase Ib)Drug
200 mg subcutaneous (s.c) once
Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 300 mg (phase Ib)Drug
300 mg subcutaneous (s.c) once
Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 200 mg (phase II)Drug
one s.c. injection of SSGJ-613 once, on Day 1.
Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection low dose 300 mg (phase II)Drug
one s.c. injection of SSGJ-613 once, on Day 1.
Compound Betamethasone Injection (phase II)Drug
1 mL i.m. once on Day 1
Placebo (phase II)Other
Participants will receive Placebo matching SSGJ-613 to maintain the blinding of the Investigational Medicinal Products.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase Ib: Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: From baseline through 24 weeks
- Phase Ib: Incidence and Severity of Abnormalities in Vital Signs/Physical Examinations, Laboratory Examinations and Other Relevant ExaminationsTime frame: From baseline through 24 weeks
- Phase II: The Change in Pain Intensity in the Target Joint From Baseline to 72 Hours Post Dose as Measured on a 0-100 mm Visual Analog Scale (VAS)Time frame: Baseline, at 72 hrs post-dose
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Site 02
Wuhan, Hubei, China · Recruiting
Site 03
Linyi, Shandong, China · Not yet recruiting
Site 01
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.